ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma

ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma

Abstract Background Immunocheckpoint inhibitors (ICIs) have been widely used in the clinical treatment of lung cancer. Although clinical studies and trials have shown that patients can benefit significantly after PD-1/PD-L1 blocking therapy, less than 20% of patients can benefit from ICIs therapy du...

Full description

Bibliographic Details
Main Authors: Tongyuan Qu, Wenshuai Zhang, Chenhui Yan, Danyang Ren, Yalei Wang, Yuhong Guo, Qianru Guo, Jinpeng Wang, Liren Liu, Lei Han, Lingmei Li, Qiujuan Huang, Lu Cao, Zhaoxiang Ye, Bin Zhang, Qiang Zhao, Wenfeng Cao
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Journal of Translational Medicine
Subjects:
ISG15/ISGylation
Glycosylated PD-L1
Anticancer immunity
Lung adenocarcinoma
Online Access:https://doi.org/10.1186/s12967-023-04135-1

Internet

https://doi.org/10.1186/s12967-023-04135-1

Similar Items